219 related articles for article (PubMed ID: 16585216)
21. Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers.
Suzuki M; Kato-Nakano M; Kawamoto S; Furuya A; Abe Y; Misaka H; Kimoto N; Nakamura K; Ohta S; Ando H
Cancer Sci; 2009 Sep; 100(9):1623-30. PubMed ID: 19555390
[TBL] [Abstract][Full Text] [Related]
22. Expression of complement restriction factors (CD46, CD55 & CD59) in head and neck squamous cell carcinomas.
Ravindranath NM; Shuler C
J Oral Pathol Med; 2006 Oct; 35(9):560-7. PubMed ID: 16968237
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis B virus sensitizes hepatocytes to complement-dependent cytotoxicity through downregulating CD59.
Qu Z; Liang X; Liu Y; Du J; Liu S; Sun W
Mol Immunol; 2009 Dec; 47(2-3):283-9. PubMed ID: 19804910
[TBL] [Abstract][Full Text] [Related]
24. Complement regulatory proteins in normal human esophagus and esophageal squamous cell carcinoma.
Shimo K; Mizuno M; Nasu J; Hiraoka S; Makidono C; Okazaki H; Yamamoto K; Okada H; Fujita T; Shiratori Y
J Gastroenterol Hepatol; 2004 Jun; 19(6):643-7. PubMed ID: 15151618
[TBL] [Abstract][Full Text] [Related]
25. CD55 limits sensitivity to complement-dependent cytolysis triggered by heterologous expression of α-gal xenoantigen in colon tumor cells.
Wu Y; Wang Y; Qin F; Wang Z; Wang Y; Yang Y; Zheng H; Wang Y
Am J Physiol Gastrointest Liver Physiol; 2014 Jun; 306(12):G1056-64. PubMed ID: 24763553
[TBL] [Abstract][Full Text] [Related]
26. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
[TBL] [Abstract][Full Text] [Related]
27. Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies.
Figini M; Ferri R; Mezzanzanica D; Bagnoli M; Luison E; Miotti S; Canevari S
Gene Ther; 2003 Jun; 10(12):1018-25. PubMed ID: 12776159
[TBL] [Abstract][Full Text] [Related]
28. [Study of immunization protocol of ovarian carcinoma associated 6B11 anti-idiotypical minibody].
Zhu HL; Li Y; Chang XH; Cui H; Feng J; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):52-6. PubMed ID: 16635330
[TBL] [Abstract][Full Text] [Related]
29. Porcine complement regulators protect aortic smooth muscle cells poorly against human complement-induced lysis and proliferation: consequences for xenotransplantation.
Capey S; van den Berg CW
Xenotransplantation; 2005 May; 12(3):217-26. PubMed ID: 15807772
[TBL] [Abstract][Full Text] [Related]
30. Expression of complement regulatory proteins on human natural killer cell subsets.
Wang L; Halliday D; Johnson PM; Christmas SE
Immunol Lett; 2007 Oct; 112(2):104-9. PubMed ID: 17719652
[TBL] [Abstract][Full Text] [Related]
31. C-reactive protein upregulates complement-inhibitory factors in endothelial cells.
Li SH; Szmitko PE; Weisel RD; Wang CH; Fedak PW; Li RK; Mickle DA; Verma S
Circulation; 2004 Feb; 109(7):833-6. PubMed ID: 14967730
[TBL] [Abstract][Full Text] [Related]
32. [Cytotoxic action of monoclonal antibodies OC125 and SH-9 on ovarian cancer cell lines].
Murakami F
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Feb; 48(2):125-32. PubMed ID: 8718548
[TBL] [Abstract][Full Text] [Related]
33. Expression of membrane complement regulators, CD46, CD55 and CD59, in mesothelial cells of patients on peritoneal dialysis therapy.
Sei Y; Mizuno M; Suzuki Y; Imai M; Higashide K; Harris CL; Sakata F; Iguchi D; Fujiwara M; Kodera Y; Maruyama S; Matsuo S; Ito Y
Mol Immunol; 2015 Jun; 65(2):302-9. PubMed ID: 25725314
[TBL] [Abstract][Full Text] [Related]
34. The novel chimeric anti-NCAM (neural cell adhesion molecule) antibody ch.MK1 displays antitumor activity in SCID mice but does not activate complement-dependent cytolysis (CDC).
Klehr M; Koehl U; Mühlenhoff M; Tawadros S; Fischer T; Schomäcker K; Heuckmann JM; Bochennek K; Jensen M
J Immunother; 2009 Jun; 32(5):442-51. PubMed ID: 19609236
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
[TBL] [Abstract][Full Text] [Related]
36. Complement regulator loss on apoptotic neuronal cells causes increased complement activation and promotes both phagocytosis and cell lysis.
Cole DS; Hughes TR; Gasque P; Morgan BP
Mol Immunol; 2006 May; 43(12):1953-64. PubMed ID: 16406094
[TBL] [Abstract][Full Text] [Related]
37. Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells.
De Nardo C; Fonsatti E; Sigalotti L; Calabrò L; Colizzi F; Cortini E; Coral S; Altomonte M; Maio M
J Cell Physiol; 2002 Feb; 190(2):200-6. PubMed ID: 11807824
[TBL] [Abstract][Full Text] [Related]
38. Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer.
Rushmere NK; Knowlden JM; Gee JM; Harper ME; Robertson JF; Morgan BP; Nicholson RI
Int J Cancer; 2004 Mar; 108(6):930-6. PubMed ID: 14712499
[TBL] [Abstract][Full Text] [Related]
39. Co-expression of the complement regulatory proteins human DAF and CD59 with an IRES-mediated dicistronic mammalian vector enhances their cell protective effects.
Xu L; Shao H; Wu W; Cao Z; Zhao Z; Liu H; Jiang D; Mao X; Li W
Int J Mol Med; 2005 Sep; 16(3):409-14. PubMed ID: 16077947
[TBL] [Abstract][Full Text] [Related]
40. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
